Piper Sandler on Kymera Therapeutics (KYMR): 'All Eyes on BroADen2 Data in 4Q'

September 23, 2026 8:41 AM

Piper Sandler analyst Biren Amin reiterated an Overweight rating and $140.00 price target on Kymera Therapeutics (NASDAQ: KYMR).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found